Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02352896 · ClinicalTrials.gov registry record · Phase 2

Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome

A Phase 2 study, sponsored by PTC Therapeutics.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target

NCT02352896 is a Phase 2 study that has completed, run by PTC Therapeutics. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02352896, a Phase 2 study, has completed, sponsored by PTC Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target

Study Summary

EPI-743 in Leigh syndrome participants that participated in previous EPI743-12-002 (NCT01721733) study.

Interventions

  • DRUG EPI-743

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2014-01-31
Est. Completion 2023-10-30
Phase Phase 2

Sponsor

PTC Therapeutics

52 total trials

What the Registry Record Tells You About NCT02352896

The ClinicalTrials.gov registry entry for NCT02352896 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which EPI-743 is the first listed.

NCT02352896 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02352896 about?

NCT02352896 is a clinical study titled "Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome". EPI-743 in Leigh syndrome participants that participated in previous EPI743-12-002 (NCT01721733) study.

What is the current status of trial NCT02352896?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2014-01-31. Estimated completion is 2023-10-30.

What interventions are being tested in trial NCT02352896?

The interventions under investigation include: EPI-743 (DRUG).

Who is sponsoring clinical trial NCT02352896?

This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.